What do systematic reviews say?

Summary of findings: repaglinide vs insulin

Summary of findings: repaglinide showed no clear difference in FVC % predicted change from baseline compared with insulin (moderate certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 112 participants
  Moderate

Summary of findings: NPH insulin vs insulin glargine

The review found no eligible studies for this question.

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: NPH insulin vs insulin glargine

The review found no eligible studies for this question.

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Insulin vs placebo

Summary of findings: insulin showed no clear difference in FEV1 % predicted: change from baseline compared with placebo (low certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  MD 1.2
  1 study · 39 participants
  Low

Insulin vs placebo

Summary of findings: insulin showed no clear difference in FVC % predicted: change from baseline compared with placebo (low certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  MD 0.6
  1 study · 39 participants
  Low

Summary of findings: repaglinide vs placebo

Summary of findings: repaglinide showed no clear difference in FEV1 % predicted; change from baseline compared with placebo (low certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  MD 1.7
  1 study · 38 participants
  Low

Summary of findings: repaglinide vs placebo

Summary of findings: repaglinide showed no clear difference in FVC % predicted: change from baseline compared with placebo (low certainty).

• Drug treatments for managing cystic fibrosis‐related diabetes 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Low

Respiratory muscle training vs control

• Respiratory muscle training for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 83 participants
  Very low

Respiratory muscle training vs control

• Respiratory muscle training for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 72 participants
  Very low

Respiratory muscle training vs control

• Respiratory muscle training for cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 87 participants
  Very low

Oscillating devices vs PEP

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  15 studies · 510 participants
  Very low

Oscillating devices vs conventional physiotherapy

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 363 participants
  Very low

Oscillating devices vs conventional physiotherapy

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 319 participants
  Very low

Oscillating devices vs PEP

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 355 participants
  Very low

Oscillating devices vs breathing techniques

• Oscillating devices for airway clearance in people with cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 210 participants
  Low

Summary of findings for combination antimicrobial susceptibility testing vs conventional treatment (separate testing)

The review found no eligible studies for this question.

• Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: β‐carotene vs placebo

Summary of findings: β‐carotene showed no clear difference in respiratory function absolute FEV1 % predicted compared with placebo (low certainty).

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Low

Summary of findings: nitric oxide vs placebo

Summary of findings: nitric oxide showed no clear difference in respiratory function mean change in FEV1 % predicted from baseline compared with placebo (low certainty).

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 12 participants
  Low

Zinc vs placebo

It is very uncertain whether summary of findings: Zinc supplementation changes respiratory function mean FEV1 % predicted compared with placebo (very low certainty).

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 62 participants
  Very low

Summary of findings: garlic supplementation vs placebo

Summary of findings: garlic supplementation showed no clear difference in respiratory function change from baseline in % predicted FEV1 compared with placebo (moderate certainty).

• Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
  MD 1.59
  1 study · 26 participants
  Moderate